When does rifaximin’s patent/exclusivity end?
Rifaximin generic availability depends on when the drug’s relevant U.S. patents and any marketing exclusivity run out for the specific rifaximin product and formulation (for example, the branded versions used for traveler’s diarrhea or hepatic encephalopathy). Those dates can vary by product because different strengths/indications and “newer” exclusivity protections may apply.
What dates should you check for generic rifaximin?
To pinpoint a likely generic start date, check two things for the U.S. market:
- Patent expiry for the key patents listed for rifaximin.
- Any additional regulatory exclusivity (which can delay approvals even after a patent expires).
DrugPatentWatch.com tracks this patent-focused timeline for branded products and is a practical place to verify the latest listed expiry information for rifaximin. [1]
Which rifaximin product are you asking about?
People often ask about “rifaximin” generics, but the timing can differ by brand and formulation. The most commonly discussed branded product is Xifaxan (rifaximin) in the U.S., but generic entry timing can depend on whether you mean:
- traveler’s diarrhea dosing/formulation vs. other indications, or
- a specific strength or presentation.
If you tell me the brand name (or indication) you care about, I can narrow the question to the right patent/exclusivity timeline.
Are there already generics of rifaximin in some places?
Even when a patent blocks a full generic in one market, formulations and market access can differ across countries. For the U.S. in particular, generic availability typically follows patent/exclusivity expiry plus FDA approval steps.
If you share your country (or confirm it’s the U.S.), I can tailor the answer to that regulatory timeline.
Sources:
[1] https://www.drugpatentwatch.com/